The company will not receive any proceeds from the sale of the shares of its common stock by the selling stockholders.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INDP:
- Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
- Indaptus Therapeutics to initiate dosing of patients at higher Decoy20 dose
- Indaptus Therapeutics sees cash runway into 1Q25
- Indaptus Therapeutics reports Q2 EPS (47c) vs. (39c) last year
- Indaptus Therapeutics announces $3M registered direct offering